ArticleHeliyon2025
Keystone bacteria dynamics in chronic obstructive pulmonary disease (COPD): Towards differential diagnosis and probiotic candidates.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Mycobacterium tuberculosis infection disrupts gut and respiratory microbial communities and networks with incomplete restoration after two months of treatment.Gut pathogens · 2026Article
- Crosstalk between the microbiome and the mucosal immunoglobulin A system in the lung, in health and disease.Frontiers in cellular and infection microbiology · 2026Review
- From the gut to the lungs: The role of gut microbiota in chronic obstructive pulmonary disease and related research progress.Microbial cell (Graz, Austria) · 2026Article
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
- Research Advances on the Impact of Gut Microbiota on COPD: Exploring New Perspectives on the Microbiota-Gut-Lung Axis.Current microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preventing exacerbations in Chronic Obstructive Pulmonary Disease (COPD) is crucial due to the high mortality rate and the associated costs of hospitalization for patients during exacerbations. Despite the proven influence of the lung microbiome on disease control, the dynamics of bacterial communication in different stages of COPD remain unknown. This study aimed to propose a group of candidate bacteria for the differential diagnosis of different states of COPD based on the relative abundance correlation of bacteria in lung sputum samples. We compared microbiome data collected from 101 COPD patients in stable and exacerbation states, as well as 124 healthy controls from two separate general cohorts, to determine the major microbiome and keystone genera. To validate our findings, we utilized two additional distinct public datasets, each comprising 81 healthy subjects and 87 COPD patients in stable condition, exacerbation, and post-treatment phases. During COPD exacerbation,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.